Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selatogrel self-administration for recurrent acute myocardial infarction prevention and treatment
2020-000983-41Phase 3Active
- Sponsor
- Idorsia
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Selatogrel with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2021; status: active.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2020-000983-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000983-41.